Adam R. Levy Sells 4,000 Shares of NEXGEL, Inc. (NASDAQ:NXGL) Stock

NEXGEL, Inc. (NASDAQ:NXGL) CEO Adam R. Levy sold 4,000 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $3.64, for a total value of $14,560.00. Following the completion of the sale, the chief executive officer now directly owns 378,284 shares in the company, valued at $1,376,953.76. This represents a 1.05 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

NEXGEL Stock Performance

Shares of NEXGEL stock opened at $3.38 on Friday. The company has a 50 day moving average of $3.86 and a 200 day moving average of $3.20. NEXGEL, Inc. has a 52-week low of $1.84 and a 52-week high of $5.10. The company has a current ratio of 1.51, a quick ratio of 0.93 and a debt-to-equity ratio of 0.19.

Institutional Trading of NEXGEL

A hedge fund recently raised its stake in NEXGEL stock. Northeast Financial Group Inc. boosted its holdings in NEXGEL, Inc. (NASDAQ:NXGL) by 168.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,848 shares of the company’s stock after purchasing an additional 20,000 shares during the quarter. Northeast Financial Group Inc. owned about 0.50% of NEXGEL worth $82,000 as of its most recent SEC filing. 2.21% of the stock is owned by institutional investors and hedge funds.

NEXGEL Company Profile

NEXGEL, Inc manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc and changed its name to NEXGEL, Inc in November 2019.